A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

NCT00361504 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1123

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Hip
Osteoarthritis, Knee
Lower Back Pain
Pain

Interventions

DRUG: Oxycodone CR
DRUG: Tapentadol (CG5503) ER

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]